Trexquant Investment LP Has $4.48 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Trexquant Investment LP grew its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 241.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,548 shares of the company's stock after acquiring an additional 212,552 shares during the period. Trexquant Investment LP owned 0.33% of Arcus Biosciences worth $4,475,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. R Squared Ltd acquired a new stake in Arcus Biosciences in the 4th quarter valued at about $26,000. US Bancorp DE boosted its stake in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after acquiring an additional 6,615 shares during the last quarter. AXQ Capital LP bought a new stake in shares of Arcus Biosciences during the 4th quarter valued at $160,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Arcus Biosciences during the fourth quarter worth $207,000. Finally, Teacher Retirement System of Texas increased its holdings in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock valued at $223,000 after purchasing an additional 2,410 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RCUS. Bank of America decreased their target price on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Morgan Stanley cut their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Finally, HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their price objective for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences has an average rating of "Buy" and a consensus price target of $30.25.

Remove Ads

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CEO Terry J. Rosen purchased 19,800 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Yasunori Kaneko purchased 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company's stock.

Arcus Biosciences Stock Down 9.7 %

Arcus Biosciences stock traded down $0.77 during mid-day trading on Thursday, reaching $7.17. The company's stock had a trading volume of 295,109 shares, compared to its average volume of 989,667. The business's 50 day simple moving average is $9.92 and its 200 day simple moving average is $13.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $18.98. The company has a market capitalization of $754.05 million, a price-to-earnings ratio of -2.29 and a beta of 1.54.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.